Prodrug Design and Drug Delivery Strategies

Prodrugs are chemically modified derivatives of therapeutic agents that remain inactive until conversion to their parent drugs in vivo. This approach addresses many obstacles in drug development, including poor aqueous solubility, limited membrane permeability and rapid metabolic clearance. Classical prodrug design focuses on altering physicochemical properties—such as lipophilicity or charge state—through covalent attachment of promoieties that are cleaved enzymatically or by environmental triggers. Modern strategies integrate molecular targeting, exploiting specific transporters, tissue-selective enzymes or pathological microenvironments to achieve site-directed activation and minimise off-target effects. Advances in nanoformulations, lipid conjugation and computational modelling now allow rational tuning of release kinetics, biodistribution and pharmacokinetic profiles. Collectively, these innovations underpin a versatile toolbox that accelerates drug discovery, refines therapeutic index and expands treatment options across oncology, neurology and infectious diseases.

Research from Nature Portfolio

Recent studies have demonstrated the power of nanocarrier-based prodrugs in enhancing selectivity and efficacy. One seminal work developed a paclitaxel-vitamin E conjugate linked via a disulfide bond and formulated into a lipid-rich nanoemulsion. The system exhibits prolonged circulation and remains stable in plasma but undergoes rapid bond cleavage within glutathione-rich tumour microenvironments, unmasking the active drug. In vitro assays showed increased cytotoxicity against cancer cells, while in vivo models revealed significant tumour regression after repeated administration. This strategy exemplifies how reduction-sensitive linkers and lipidic carriers can be combined to achieve tumour-selective activation and improved therapeutic outcomes.

Prodrug Design and Drug Delivery Strategies publication trend

The graph below shows the total number of articles in prodrug design and drug delivery strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Prodrug: An inactive or less active derivative of a drug designed to undergo biotransformation in the body to release the active parent compound.

Promoiety: A chemical group covalently attached to a drug moiety in a prodrug, conferring improved properties and subject to cleavage in vivo.

Nanocarrier: A nanoscale vehicle—such as a liposome, polymeric nanoparticle or nanoemulsion—used to encapsulate or conjugate drugs for controlled delivery.

Lipidic prodrug: A prodrug in which the active drug is linked to a lipid molecule, exploiting lipid processing pathways to enhance absorption, targeting or barrier penetration.

Molecular docking: A computational method that predicts the preferred orientation of a small molecule within an enzyme or receptor binding site.

Molecular dynamics simulations: Computer simulations that model the time-dependent behaviour of molecular systems, used to assess stability and interactions of prodrug–enzyme complexes.

References

1. Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly. Scientific Reports (2015).
2. Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery. Journal of Nanobiotechnology (2022).
3. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics (2020).
4. Computational Simulations to Guide Enzyme-Mediated Prodrug Activation. International Journal of Molecular Sciences (2020).